{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019700","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.792438+00:00","generated_at":"2026-06-07T15:28:47.359929+00:00","sec_items":["1.01","3.02","3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ProMIS Neurosciences exchanges Series 1 Preferred for Series 2 at 60:1; no Series 1 outstanding","bullets":["70,000,000 Series 1 Preferred exchanged for 1,166,667 Series 2 Preferred (60:1 ratio).","Series 2 Preferred automatically converts into Common upon $14M+ equity financing (Mandatory Conversion Event).","Prior nine-month financing limitation terminates as of December 4, 2023.","Amended articles to create Series 2; rights substantially similar to Series 1 except conversion trigger.","Holders include Crocker Mountain, Kraft entities, McCance Trust, and others."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019700","json":"https://secwatch.observer/filing/0001558370-23-019700.json","markdown":"https://secwatch.observer/filing/0001558370-23-019700.md","text":"https://secwatch.observer/filing/0001558370-23-019700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/0001558370-23-019700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/pmn-20231204x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:28:47.359929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0fe6309980d4628fcbb28f23ef85041a2bac8571","claim":"ProMIS Neurosciences Inc.: The Company filed articles of amendment to create a new class of Series 2 Preferred Shares, effective December 4, 2023 (effective 2023-12-04).","evidence_excerpt":"Effective as of December 4, 2023, the Company filed articles of amendment (the “ Articles of Amendment ”) to amend its articles to create the new class of Series 2 Preferred Shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/0001558370-23-019700-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-04"}],"fact_type":"governance_change"},{"claim_id":"033ef0d16e4b7a6a3bf82e581c5b21cca92313bf","claim":"ProMIS Neurosciences Inc. entered into Exchange Agreement with the holders of the Company's Series 1 convertible preferred shares (effective 2023-12-04).","evidence_excerpt":"On December 4, 2023, Promis Neurosciences, Inc. (the “ Company ”) entered into a Share Exchange Agreement (the “ Exchange Agreement ”) with the holders (the “ Holders ”) of the Company’s Series 1 convertible preferred shares (the “ Series 1 Preferred Shares ”), pursuant to which the Series 1 Preferred Shares were exchanged for a new class of Series 2 convertible preferred shares (the “ Series 2 Preferred Shares ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1374339/000155837023019700/0001558370-23-019700-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the holders of the Company's Series 1 convertible preferred shares"},{"label":"Effective","value":"2023-12-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}